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Humanainly expressed in activated CD4+T cells and interacts with CD40 on antigen-
presenting cells to regulate both humoral and cellular immune responses. We previously reported that
CD40L is acquired by emerging HIV-1 particles. Here we demonstrate that both wild-type and a non-
functional mutated form of CD40L are incorporated within HIV-1. Importantly, we show that wild-type
CD40L remains functional since CD40L-bearing virions mediate NF-κB activation in a CD40-expressing
reporter cell line and induce secretion of the chemokine IL-8 by monocyte-derived macrophages. These
results suggest a possible means exploited by HIV-1 to attract susceptible target cells to the site of infection, a
process that might promote viral dissemination.
© 2008 Elsevier Inc. All rights reserved.IntroductionInteractions between CD40 and CD40 ligand (CD40L) play a pivotal,
non-redundant role in the initiation and regulation of both humoral
and cell-mediated immunity (reviewed in Mackey, Barth, and Noelle,
1998). The demonstration of the physiological importance of CD40/
CD40L interactions came from the discovery that the hyper-IgM
syndrome, an X-linked immunodeﬁciency, is due to a genetic
alteration of the CD40L gene (Thusberg and Vihinen, 2007). This
disease is characterized by a severe impairment of T cell-dependent
antibody responses with no B cell memory, deﬁcient induction of
somatic mutations, and little or no circulating IgG, IgA, or IgE
antibodies (Schneider, 2000). CD40L is a type II transmembrane
trimeric protein that belongs to the tumor necrosis factor (TNF) family.
It is now recognized that CD40L is primarily expressed on the surface
of CD4+T cells upon cellular activation but not on resting cells. As for
CD40, a type I membrane protein in the TNF receptor family, it is
constitutively expressed on antigen-presenting cells (APCs) (e.g. B
cells, macrophages, and dendritic cells).
Macrophages, as APCs, are rapidly involved in the immune
response directed against human immunodeﬁciency virus type 1
(HIV-1). These cells play a dominant role, linking innate to acquired
immunity. Interactions between CD40, on macrophages, and CD40L,
on CD4+T lymphocytes, are crucial to the activation of these two cellvirologie Humaine, Centre de
uébec (QC), Canada G1V 4G2.
M.J. Tremblay).
l rights reserved.types upon creation of the immunological synapse. This interplay
results in the production of a vast array of soluble factors, such as
interleukin (IL)-1, IL-8 and TNF-α, which all participate in the
establishment of an inﬂammatory milieu (Bergamini et al., 2002;
Bolacchi et al., 2001; Cotter et al., 2001; Kiener et al., 1995).
We reported previously that host-derived CD40L molecules are
acquired by clinical HIV-1 isolates expanded in peripheral blood
mononuclear cells (PBMCs) and lymphoid tissue (Martin and
Tremblay, 2004). More recently, we demonstrated that the presence
of CD40L at the surface of HIV-1 particles can induce homotypic
cellular adhesion, immunoglobulin G production, as well as IL-6
secretion upon binding of virus to primary B lymphocytes (Martin et
al., 2007). Given that macrophages do express CD40 and are
considered as key targets for HIV-1 infection, we tested the capacity
of virus-anchored CD40L to activate human primary monocyte-
derived-macrophages (MDMs) by measuring the secretion of the
CXC chemokine IL-8.
Results
Both wild-type and mutated CD40L are acquired by HIV-1
We ﬁrst produced four different viral stocks by calcium-phosphate
transfection of 293Tcellswith the R5-tropic infectiousmolecular clone
pNL4-3Balenv that was co-transfected either with an empty control
vector to produce virions lacking CD40L (parental 293T cells are
negative for CD40L) or an expression vector coding for the human
wild-type CD40L to generate viruses bearing host-derived CD40L. This
task was achieved using a previously described transient transfection-
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stock carrying a mutated version of CD40L, which is characterized by a
point mutation consisting in the substitution of an asparagine for a
threonine at position 147 (T147N). This single-point mutation is found
in patients afﬂictedwith the X-linked hyper-IgM syndrome and results
in a non-functional CD40L that can no longer interacts with CD40. As
depicted in Fig.1, surface expression levels of wild-type CD40L and the
T147N mutant vary amongst the virus producer 293T cells.
The next step was to verify whether both wild-type and mutated
CD40L were effectively acquired by HIV-1 through the use of a plate
immunocapture assay coated with an antibody speciﬁc for CD40L
(clone M90.1, BD Pharmingen) as previously described (Beauséjour
and Tremblay, 2004). Results from the virus capture test indicate
that the levels of incorporation of wild-type CD40L are variableFig. 1. Surface expression of CD40L on transiently transfected 293T cells. Cell surface express
ﬁrst labeled with a primary anti-CD40L monoclonal antibody (M90.1) followed by a seconda
was used as a control (gray histograms). The percentages of CD40L-expressing cells and theamongst the viral stocks tested (Fig. 2A). Interestingly, the T147N
mutant is incorporated as efﬁciently in emerging virions as wild-
type CD40L (Fig. 2B). Altogether data from ﬂow cytometry analyses
and the virus capture assay indicate that the variability in the
incorporation process of host-derived CD40L does not seem to be
linked with the amounts of CD40L expressed on the surface of 293T
cells (compare Figs. 1 and 2).
CD40L remains functional once incorporated within viruses
Next, we addressed the biological activity of host-derived CD40L
molecules once inserted within virions. This goal was reached by
using a 293-derived reporter cell line engineered to express CD40
(i.e. CD40-293-SEAP), the natural counter-receptor of CD40L.ion of CD40L on virus producer 293T cells was monitored by ﬂow cytometry. Cells were
ry ﬂuorochrome-labeled antibody (black lines). An isotype-matched irrelevant antibody
mean ﬂuorescence intensity values are presented in the table.
Fig. 2. Wild-type and mutated CD40L are acquired by HIV-1. (A) 293T cells were either
cotransfected with pNL4-3Balenv and an empty control vector (HIV) or cotransfected
with pNL4-3Balenv and the pcDNA3.1-CD40L expression vector (HIV/CD40L). Virus
preparations originated from 4 independent transfections. (B) In some experiments,
virus preparations were made by cotransfection of 293T cells with an expression vector
coding either for wild-type (HIV/CD40L) or mutated CD40 (HIV/T147N). Similar
amounts of the indicated virus stocks, standardized in terms of p24, were next
incubated in a plate immunocapture assay. The levels of captured viruses were
estimated with the use of a p24 test. The data shown represent the means±SEM of
triplicate samples. The baseline values obtained from an isotype-matched control
antibody have been subtracted from each value.
Fig. 3. Virus-associated CD40L remains functional. (A) Paraformaldehyde-ﬁxed 293T
cells either negative (i.e. parental) or positive for CD40L (i.e. transiently transfectedwith
the vector coding for wild-type CD40L) were co-cultured with CD40-expressing 293
reporter cells (i.e. CD40-293-SEAP) at the listed ratio (i.e. 1:1, 1:2, 1:5 and 1:10). (B)
CD40-293-SEAP reporter cells were either left unexposed or exposed to virions lacking
CD40L, CD40L-bearing virions, or cell-free supernatants from 293T cells transfected
with the CD40L expression vector only (mock). Virus stocks from the 4 independent
transfections were tested. (C) In some experiments, comparative studies were made
between viruses bearing either host-derived wild-type or mutated CD40L (viral stock
D). The data shown represent the means±SEM of triplicate samples. The statistical
signiﬁcance of the obtained values were analyzed with a one-way ANOVA test followed
by a Dunnett's multiple comparison post-test with the mock as a control and performed
using GraphPad Prism 4.01 (⁎⁎, Pb0.01).
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CD40L since it secretes embryonic alkaline phosphatase (SEAP) upon
NF-κB activation through the stimulation of CD40. The validity of
CD40-293-SEAP cells was assessed by measuring the functional
response of this reporter cell line to increasing proportions of
paraformaldehyde-ﬁxed CD40L-expressing 293T cells. In this set of
experiments, similarly treated parental CD40L-negative 293T cells
were used as a negative control. In contrast to what is seen with
parental CD40L-negative 293T cells, reporter gene activity was
increased in a dose-dependent manner upon co-culture of CD40-
293-SEAP cells with CD40L-positive 293T cells (Fig. 3A). Thereafter,
we monitored the ability of CD40L-bearing viruses to drive reporter
gene activity in CD40-293-SEAP cells. Brieﬂy, the reporter cells were
ﬁrst plated in each well of a 96-well plate the day before performing
the experiment. Next, cells were exposed for 24 h to isogenic viruses
either lacking or bearing host-derived wild-type CD40L. In such
studies, controls consisted of the same volume of supernatant from
293T cells transiently transfected with the CD40L expression vector
(mock). We tested with this reporter cell line the various viral stocks
depicted in Fig. 2A. Interestingly, a statistically signiﬁcant increase in
SEAP production was seen with the four CD40L-bearing virus
preparations tested but not with the corresponding isogenic virus
stocks lacking host-derived CD40L (Fig. 3B). Moreover, the T147N
mutant of CD40L was unable to induce the production of SEAP (Fig.
3C), which conﬁrms its inability to interact with CD40. Therefore, the
incorporation of CD40L within HIV-1 does not alter its natural
capacity to interact with CD40 and to drive signal transduction
leading to NF-κB activation.CD40L-bearing viruses induce secretion of IL-8 by MDMs
It has been well established that stimulation of MDMs by soluble
CD40L induces the secretion of IL-8 (Kiener et al., 1995), a well-known
chemoattractant for neutrophils, and to a lesser extent, for T
lymphocytes (Larsen et al., 1989; Leonard et al., 1990). It can be
Fig. 4.HIV-1-associated CD40L induces secretion of IL-8 byMDMs. Similar amounts of virus preparations originating from the 4 independent transfections were incubated for 24 h at
37 °C with MDMs (panels A to D). Levels of IL-8 were then quantiﬁed through the use of a commercial ELISA test. In some experiments, MDMs were incubated with
paraformaldehyde-ﬁxed parental 293T cells (CD40L-negative) or 293T cells transfected with the CD40L expression vector (293T/CD40L) (panels B to D), whereas some studies were
performed with isogenic viruses bearing either host-derived wild-type or mutated CD40L (panel D). The data shown represent the means±SEM of triplicate samples. The statistical
signiﬁcance of the obtained values were analyzedwith a one-way ANOVA test followed by a Dunnett's multiple comparison post-test with themock as a control and performed using
GraphPad Prism 4.01 (⁎⁎, Pb0.01).
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cytes by macrophages interacting with CD40L-bearing viruses could
facilitate the propagation of HIV-1. Our next objective was thus to
determine if the presence of host-derived CD40L on the exterior of
HIV-1 particles can promote the secretion of this chemokine by
MDMs. The cells were derived from a 7-day long differentiation of
monocytes puriﬁed by plastic adherence in a culture mediummade of
RPMI-1640 supplemented with 5% heat-inactivated autologous serum
and 25 ng/mL of macrophage-colony stimulating factor. Fully
differentiated MDMs (2×105) were then exposed to the different
virus preparations listed in Fig. 2 (a ﬁnal concentration of 40 ng of p24
was used). Again, cell-free supernatants from 293T cells transiently
transfected with the vector coding for wild-type CD40L were used as
controls in each instance (mock). In some experiments, additional
controls were included that consisted of paraformaldehyde-ﬁxed
293T cells (1×105) either transiently transfected with an empty
control vector or the molecular construct coding for wild-type CD40L.
Finally, production of IL-8 was monitored with a commercial
sandwich ELISA test (human CXCL8/IL-8 DuoSet, R and D Systems,
Minneapolis, MN). A statistically signiﬁcant production of IL-8 by
MDMswas seenwhen using CD40L-bearing virus preparations (Fig. 4).
Secretion of IL-8 was more important in such samples as compared to
what is seen in mock-infected MDMs and cells exposed to virions
lacking CD40L. In addition, viruses carrying the T147N mutant of
CD40L were unable to induce any signiﬁcant production of IL-8 by
MDMs. However, we did observe some variability in the induction ofIL-8 secretion between the different viral preparations and donors
tested (data not shown). For example, a single virus preparation
bearing wild-type CD40L could trigger IL-8 production in MDMs from
only one of the two different donors studied (data not shown),
therefore implying that secretion of IL-8 is inﬂuenced primarily by the
responding MDMs and less by the CD40L-bearing virus preparation.
Additional studies are necessary to address this issue in a more
detailed manner and to deﬁne for example if the surface expression
levels of CD40 inMDMs could account for the different responsiveness
to CD40L-bearing viruses.
Discussion
Overall our data conﬁrm the previous observations demonstrating
that host-derived CD40L molecules are still functional when found
embedded within HIV-1 particles (Martin et al., 2007). In the present
work, the capacity of CD40L-bearing virions to elicit IL-8 production
by human primary MDMs was illustrated through the use of viral
stocks produced following transient transfection of 293T cells. The
artiﬁcial nature of the experimental cell system used to generate the
tested virus preparations might weaken the physiological signiﬁcance
of our observations. However, this strategy carries a signiﬁcant
advantage since it allows performing side-by-side comparative
studies with isogenic viruses that are either lacking or bearing host-
derived CD40L. Importantly it permits also to test virions carrying a
mutated CD40L molecule that can no longer interact with its normal
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allowed us to validate the biological activity of virus-associated host
CD40L. It is important to state that it is difﬁcult to perform similar
experiments with PBMCs-derived clinical and/or laboratory isolates of
HIV-1 because the functionality of virus-associated host CD40L would
have to be addressed with the use of antibodies blocking the natural
interaction between CD40 and CD40L. In such studies, an anti-CD40
antibody would have to be used to avoid any steric hindrance
phenomenon mediated by an antibody speciﬁc for virus-anchored
host CD40L. Indeed, an anti-CD40L antibody might jeopardize the
natural interactions between virus-associated gp120 and CD4. On the
other hand, the use of an anti-CD40 to demonstrate the ability of
virus-anchored host CD40L to mediate secretion of IL-8 in human
primary MDMs is also subjected to a severe limitation. Indeed, it has
been shown that antibody-mediated homotypic aggregation of Fc
receptors on monocytic cells induces the expression of several soluble
factors including IL-8 (Fernandez et al., 2002). Therefore, although
viruses expanded in human primary cells are likely to better reﬂect
the natural conditions, there are several factors that impede their use
to demonstrate the functionality of virus-anchored cell surface
molecules of host origin.
Since IL-8 acts as a chemoattractant for CD4+T cells, the results of
the present study suggest a possible means exploited by HIV-1 to
attract such preferential target cells to the infection site, a
phenomenon that might promote virus replication. Moreover, a
previous work demonstrated that IL-8 stimulates viral production in
both macrophages and CD4+T lymphocytes (Lane et al., 2001).
Importantly, it has been reported that the basal expression of CD40L
is increased in T cells from HIV-1-infected individuals with high
blood CD4 counts (Muller et al., 1998; Sousa et al., 1999; Zhang et al.,
2004), which provides credence to our ﬁndings. This might increase
the probability for the virus to incorporate host-derived CD40L
during the budding process. Because of its known physiological
functions, IL-8 participates in the establishment of a pro-inﬂamma-
tory microenvironment that causes a systemic immune activation
and an overexpression of matrix metalloproteinases (reviewed in
Mauviel, 1993). These proteolytic enzymes are playing a key role in a
wide range of processes including tissue remodeling and release of
biological factors. Therefore, the induction of IL-8 secretion by HIV-
1-associated host CD40L might represent another factor possibly
involved in hyperactivation of the immune system and structural
destruction of lymphoid organs, which are two features commonly
seen in the course of AIDS (Frost and McLean, 1994; Pantaleo et al.,
1994). Overall our ﬁndings conﬁrm that host-derived cell surface
constituents are still functionalwhen found embeddedwithin the viral
envelope and suggest that such foreignmolecules canmodulate HIV-1
pathogenesis.
Materials and methods
Cell culture
Human embryonic kidney 293T cells were cultured in complete
DMEM medium (i.e. DMEM supplemented with 10% fetal bovine
serum/FBS, 2 mM L-glutamine, 100 U/mL penicillin G and 100 µg/mL
streptomycin). The indicator CD40-293-SEAP cells have been engi-
neered to overexpress wild-type human CD40 and to produce the
secreted embryonic alkaline phosphatase (SEAP) upon NF-κB activa-
tion through the stimulation of cell surface CD40 (kindly supplied by
R.S. Kornbluth). These cells were cultured in DMEM medium
supplemented with 10% FBS and appropriate selective agents (i.e.
500 µg/mL of G418 and 100 µg/mL of Zeocin). Human primary
monocytes were puriﬁed by plastic adherence in complete RPMI-1640
medium supplemented with 5% heat-inactivated autologous serum.
Brieﬂy, peripheral blood mononuclear cells (1.5×107 cells/mL) were
plated in 75 cm2 ﬂasks. After 1 h, non-adherent cells were removed byseveral washes with PBS and freshly isolated monocytes were further
cultured in the samemedium for 7 days in the presence of 25 ng/mL of
macrophage-colony stimulating factor (GenScript Corporation, Piscat-
away, NJ) to derive MDMs. Thereafter, MDMs were recovered by
scraping cells with a soft cell scraper following a 15 min incubation
period with a solution made of PBS and 5 mM EDTA and cells were
plated in 24-well plates at a ﬁnal concentration of 2×105 cells per well
in complete RPMI-1640 medium supplemented with 5% autologous
human serum.
Flow cytometry analysis
To monitor cell surface expression of CD40L, transiently
transfected 293T cells were incubated with an antibody speciﬁc
for human CD40L (clone M90.1, BD Pharmingen) or an appropriate
isotype-matched irrelevant control antibody for 30 min at 4 °C.
Cells were next washed with phosphate-buffered saline (PBS) and
then incubated with an R-PE-conjugated goat anti-mouse IgG for
30 min at 4 °C. After two washes with PBS, cells were ﬁxed in 2%
paraformaldehyde and analyzed by FACS (Epics ELITE ESP, Coulter
Electronics, Burlington, ON).
Molecular constructs
pNL4.3Balenv construct was kindly provided by R.J. Pomerantz
(Thomas Jefferson University). The cDNA3.1-CD40L molecular con-
struct codes for wild-type human CD40L, whereas the cDNA3.1-
CD40L/T147N plasmid codes for a mutated version of CD40L in which
an asparagine is substituted for a threonine at position 147 (T147N).
Both cDNA3.1-CD40L and cDNA3.1-CD40L/T147N vectors were gener-
ous gifts from R.S. Kornbluth (University of California, San Diego).
Viral production
Virus particles differing only by the absence or presence of host-
derived CD40L proteins on their outer membranes were produced by
calcium-phosphate transfection of 293T cells as previously described
(Fortin et al., 1997). It should be noted that 293T cells do not express
CD40L constitutively (data not shown). Brieﬂy, 293T cells were
cotransfected with a plasmid coding for the human wild-type CD40L
molecule (i.e. pcDNA3.1-CD40L) and a plasmid coding for a R5-tropic
strain of HIV-1 (pNL4.3Balenv) at a 1:4 ratio. We also produced viruses
bearing a mutated version of CD40L where pcDNA3.1-CD40L was
replaced by pcDNA3.1-CD40L/T147N. Viruses lacking host-derived
CD40L were made by substituting an empty control vector for
pcDNA3.1-CD40L. Virus-containing supernatants were ﬁltered
through a 0.22 µm ﬁlter (Millipore) and the amount of viruses
produced was measured by an in-house enzyme-linked immunosor-
bent assay (ELISA) speciﬁc for the major core p24 protein (Bounou,
Leclerc, and Tremblay, 2002).
Immunocapture assay
The immunocapture assay was performed as described previously
(Beauséjour and Tremblay, 2004). Brieﬂy, ﬂat-bottom 96-well plates
were coated either with an anti-CD40L antibody or isotype-matched
control antibody (IgG1) (5 µg/mL) for 2 h at room temperature and
blocked for 1 h with a solution made of phosphate-buffered saline
(PBS) and BSA 1%. Then, a viral input corresponding to 25 ng of p24
was added per well. The plates were incubated overnight at 4 °C and
washed twicewith a solution of PBS. Next, 200 µL of PBS and 50 µL of a
5% Triton-X solution were added per well and the plates were
incubated for 30 min at room temperature. Finally, 125 µL were
transferred to a plate coated for our homemade p24 test. This assay
quantiﬁes the viral protein p24 recovered from the captured viral
particles, that is, the p24 associated with CD40L-bearing viruses.
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CD40-293-SEAP cells were seeded in 96-well plate (2×104 per
well) in DMEM medium supplemented with 10% FBS only. The next
day, isogenic virus preparations either lacking or bearing CD40L (wild-
type or mutated) were added to each well (16 ng of p24), and left for a
24 h period. In parallel, the same volume of mock-infected super-
natant was used as a control (i.e. supernatant from 293T cells
transfected with the expression vector coding for CD40L only). The
production of SEAP was monitored according to the manufacturer's
protocol with 20 µL of cell-free culture supernatant and the medium
for detection and quantiﬁcation of SEAP (i.e. Quanti-Blue™, Invivogen,
San Diego, CA), after a 3 h incubation period. In some studies, fully
differentiated MDMs (2×105) were exposed either to the tested virus
stocks (40 ng of p24), an equivalent volume of mock, or, as controls,
1×105 paraformaldehyde-ﬁxed 293T cells, transfected or not with
wild-type CD40L, and incubated for a 24 h time period. The presence
of IL-8 in the supernatant was determined using the IL-8 Duo-Set
ELISA from R and D Systems (Minneapolis, MN).
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